
    
      This is a Phase II, multicenter, prospective, open label, single arm study. The primary
      endpoint of the study is progression-free rate as defined by Response Evaluation Criteria in
      Solid Tumors (RECIST) guidelines version 1.1 at week 12 after start of treatment. The
      secondary endpoints include overall progression-free survival (PFS), response rate (RR),
      duration of response, overall survival (OS), and toxicity assessment through the reporting of
      adverse events.
    
  